SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Financial Toxicity Intervention Improves Outcomes in Patients With Hematologic Malignancy
16 references·0 citing·35 second hop
Financial Toxicity Intervention Improves Outcomes in Patients With Hematologic Malignancy (2022)Financial Toxicity Intervention Improves …Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies (2019)Financial toxicity in cancer …Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes (2019)Financial Burdens of Cancer T…The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment (2018)The financial burden and dist…Self‐reported financial burden of cancer care and its effect on physical and mental health‐related quality of life among US cancer survivors (2016)Self‐reported financial burde…Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST) (2016)Measuring financial toxicity …Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer (2016)Financial Insolvency as a Ris…Financial Hardships Experienced by Cancer Survivors: A Systematic Review (2016)Financial Hardships Experienc…Pricing in the Market for Anticancer Drugs (2015)Pricing in the Market for Ant…Financial Toxicity of Cancer Care: It’s Time to Intervene (2015)Financial Toxicity of Cancer …The development of a financial toxicity patient‐reported outcome in cancer: The COST measure (2014)The development of a financia…The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience (2013)The Financial Toxicity of Can…Economic Burden of Cancer Survivorship Among Adults in the United States (2013)Economic Burden of Cancer Sur…Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia (2013)Cost Sharing and Adherence to…Are survivors who report cancer‐related financial problems more likely to forgo or delay medical care? (2013)Are survivors who report canc…Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items (2009)Development of physical and m…Detecting and monitoring depression with a two-item questionnaire (PHQ-2) (2005)Detecting and monitoring depr…An Index of Factorial Simplicity (1974)Constructing validity: Basic issues in objective scale development. (1995)Methods for the Economic Evaluation of Health Care Programmes (2005)Financial Hardship Associated With Cancer in the United States: Findings From a Population-Based Sample of Adult Cancer Survivors (2015)A Systematic Review of Financial Toxicity Among Cancer Survivors: We Can’t Pay the Co-Pay (2016)The Measurement of Observer Agreement for Categorical Data (1977)The Hospital Anxiety and Depression Scale (1983)The PHQ-9 (2001)Screening for Depression in Medical Settings with the Patient Health Questionnaire (PHQ): A Diagnostic Meta-Analysis (2007)Validation of PHQ-2 and PHQ-9 to Screen for Major Depression in the Primary Care Population (2010)Intimate partner violence against adult women and its association with major depressive disorder, depressive symptoms and postpartum depression: A systematic review and meta-analysis (2012)SF-36 physical and mental health summary scales : a user's manual (1994)A 12-Item Short-Form Health Survey (1996)The Patient-Reported Outcomes Measurement Information System (PROMIS) (2007)Development and Validation of Patient-Reported Outcome Measures for Sleep Disturbance and Sleep-Related Impairments (2010)PROMIS®-29 v2.0 profile physical and mental health summary scores (2018)PROMIS® Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains (2019)Pharmacy Benefits and the Use of Drugs by the Chronically Ill (2004)Prescription drug cost sharing: associations with medication and medical utilization and spending and health. (2007)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)Population-Based Assessment of Cancer Survivors' Financial Burden and Quality of Life: A Prospective Cohort Study (2015)The high price of anticancer drugs: origins, implications, barriers, solutions (2017)Cumulative Impact of Sustained Economic Hardship on Physical, Cognitive, Psychological, and Social Functioning (1997)Linking Clinical Variables With Health-Related Quality of Life (1995)Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes (1995)Financial Toxicity in Adults With Cancer: Adverse Outcomes and Noncompliance (2018)A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States (2020)A new scale of social desirability independent of psychopathology. (1960)Health Measurement Scales: A Practical Guide to Their Development and Use (1989)The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study (2010)Stress: Appraisal and Coping (2013)Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications (2019)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Financial toxicity in cancer care: origins, impact, and solutions (2021)Navigating financial toxicity in patients with cancer: A multidisciplinary management approach (2022)
this work references cited by second hop

References

  • 2009Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items1,954 cited
  • 2005Detecting and monitoring depression with a two-item questionnaire (PHQ-2)1,470 cited
  • 2013The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience1,133 cited
  • 2016Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)928 cited
  • 2016Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer917 cited
  • 2018The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment873 cited
  • 2016Financial Hardships Experienced by Cancer Survivors: A Systematic Review861 cited
  • 2014The development of a financial toxicity patient‐reported outcome in cancer: The COST measure692 cited
  • 2015Financial Toxicity of Cancer Care: It’s Time to Intervene538 cited
  • 2013Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia500 cited
  • 2015Pricing in the Market for Anticancer Drugs452 cited
  • 2019Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes442 cited
  • 2013Are survivors who report cancer‐related financial problems more likely to forgo or delay medical care?

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

412 cited
  • 2016Self‐reported financial burden of cancer care and its effect on physical and mental health‐related quality of life among US cancer survivors362 cited
  • 2013Economic Burden of Cancer Survivorship Among Adults in the United States353 cited
  • 2019Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies337 cited
  • Cited by

    No citing works inside the corpus for this window.